Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMFIWAN)

Drug Name
NPPB Drug Info
Synonyms
5-Nitro-2-(3-phenylpropylamino)benzoic acid; 107254-86-4; UNII-3A35O9G3YZ; 5-nitro-2-[(3-phenylpropyl)amino]benzoic acid; 3A35O9G3YZ; CHEBI:34457; Benzoic acid,5-nitro-2-[(3-phenylpropyl)amino]-; Benzoic acid, 5-nitro-2-((3-phenylpropyl)amino)-; 5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB]; 5-NITRO-2-(3-PHENYLPROPYLAMINO)-BENZOIC ACID; 5-Nitro-2-(3-phenylpropylamino)benzoic Acid (NPPB); SR-01000075336; HOE-144; HOE 144; Tocris-0593; Spectrum_001814; ACMC-20c9kv; AC1L1IEV; Spectrum4_000338; Spectrum2_001477; HOE 144; 5-nitro-2-(3-phenylpropylamino) benzoic acid
Cross-matching ID
PubChem CID
4549
ChEBI ID
CHEMBL1256759
CAS Number
CAS 107254-86-4
TTD Drug ID
D08DQL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Phagosome -1.70 1.75e-2 118/152 (77.63%) ATP6V0C;DYNC1LI2;TLR4;...
Th17 cell differentiation -1.71 1.76e-2 95/107 (88.79%) HLA-DOA;TBX21;HLA-DOB;...
Th1 and Th2 cell differentiation -1.72 1.64e-2 80/92 (86.96%) HLA-DOA;TBX21;HLA-DOB;...
Systemic lupus erythematosus -1.72 1.70e-2 45/135 (33.33%) ACTN1;SNRPB;C1S;...
Antigen processing and presentation -1.72 1.77e-2 60/78 (76.92%) IFI30;CREB1;HLA-G;...
Chemokine signaling pathway -1.74 1.53e-2 163/192 (84.9%) IKBKG;ADCY6;GNB1;...
Cytokine-cytokine receptor interaction -1.75 1.44e-2 246/295 (83.39%) CCL24;ACVR1;CLCF1;...
Kaposi sarcoma-associated herpesvirus infection -1.76 1.50e-2 172/193 (89.12%) CREBBP;TLR3;GABARAPL2;...
Hematopoietic cell lineage -1.77 1.28e-2 90/99 (90.91%) KIT;ITGA4;HLA-DOA;...
Epstein-Barr virus infection -1.78 9.73e-3 189/202 (93.56%) EIF2AK2;RBPJL;PSMD12;...
Rheumatoid arthritis -1.78 1.02e-2 78/93 (83.87%) CD80;ATP6V0C;CXCL8;...
Cytosolic DNA-sensing pathway -1.82 6.72e-3 52/63 (82.54%) TBK1;POLR3F;CHUK;...
Inflammatory bowel disease -1.88 3.55e-3 58/65 (89.23%) HLA-DOA;TBX21;HLA-DOB;...
Viral protein interaction with cytokine and cytokine re... -1.89 3.76e-3 84/100 (84%) IL2RA;CCL4;CXCL10;...
JAK-STAT signaling pathway -1.90 3.99e-3 146/162 (90.12%) STAT5B;PRLR;IL7;...
Herpes simplex virus 1 infection -1.92 4.26e-3 165/498 (33.13%) SRC;BAX;IRAK1;...
NOD-like receptor signaling pathway -1.92 4.56e-3 145/181 (80.11%) MFN2;GABARAPL2;TNF;...
Malaria -1.94 3.93e-3 44/50 (88%) TNF;GYPB;ICAM1;...
Leishmaniasis -1.94 4.26e-3 67/77 (87.01%) MAPK13;IL1B;IL1A;...
Steroid biosynthesis -1.94 4.64e-3 19/20 (95%) SOAT2;CYP27B1;LIPA;...
Viral myocarditis -1.99 0.00e+0 53/60 (88.33%) RAC1;CD80;HLA-G;...
Influenza A -2.01 0.00e+0 156/172 (90.7%) MAP2K1;CXCL8;TLR4;...
Intestinal immune network for IgA production -2.06 0.00e+0 38/48 (79.17%) CD80;ICOS;PIGR;...
Type I diabetes mellitus -2.08 0.00e+0 38/43 (88.37%) HLA-G;CD86;HLA-DOA;...
Staphylococcus aureus infection -2.13 0.00e+0 72/95 (75.79%) ITGAM;ICAM1;KRT16;...
Asthma -2.19 0.00e+0 25/31 (80.65%) HLA-DOA;HLA-DOB;EPX;...
Graft-versus-host disease -2.22 0.00e+0 32/42 (76.19%) HLA-G;CD86;HLA-DOA;...
Autoimmune thyroid disease -2.25 0.00e+0 46/53 (86.79%) HLA-G;CD86;HLA-DOA;...
Allograft rejection -2.33 0.00e+0 32/38 (84.21%) HLA-G;CD86;HLA-DOA;...
PPAR signaling pathway -2.36 0.00e+0 66/74 (89.19%) ACADM;SLC27A2;FABP5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 3.33uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 3.33uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H